CROs Improve Service Delivery
Applied Clinical Trials
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago- perhaps as recent as 2005-this chart would have been reversed, when more service providers were missing expectations than exceeding them.
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago— perhaps as recent as 2005—this chart would have been reversed, when more service providers were missing expectations than exceeding them.
So why the change? We have identified the following three factors:
- The increasingly competitive CRO environment is responsible for some of the quality improvements. Disaffected customers have more options than they used to, providing CROs with all the incentive needed to tighten the bolts on their clinical operations machinery.
- Similarly, CROs are getting better at asking the right questions and identifying their customers' needs.
- And for their part, we would suggest that sponsors are also becoming more sophisticated outsourcers They are getting better at articulating their needs, making it more likely that CROs can meet them.
Sponsors Rate Satisfaction with CROs
With 20% of interactions still missing expectations more can be done. But in our experience, these relationships have come a long way—Industry Standard Reports, www.ISRreports.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
